Screener
Sarepta Therapeutics, Inc. SRPT Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | 21,508 | 5,228 | 43,221 | 9,731 |
| Interest income | (6,207) | (5,254) | (12,567) | (15,444) |
| Income tax expense (benefit) | 3,141 | (43,254) | 15,356 | 20,736 |
| Depreciation and amortization expense | 10,409 | 10,840 | 21,003 | 20,818 |
| Stock-based compensation expense | 24,472 | 37,025 | 53,871 | 78,453 |
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Segment net (loss) income | $(4,890) | $196,892 | $326,069 | $(250,616) |
| Reconciliation of profit or loss |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s business segments — D&A?
- Sarepta Therapeutics, Inc. (SRPT) reported business segments — D&A of $10.41M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s business segments — D&A changed year-over-year?
- Sarepta Therapeutics, Inc.'s business segments — D&A decreased by 4.0% year-over-year, from $10.84M to $10.41M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — D&A?
- Over 3 years (2022 to 2025), Sarepta Therapeutics, Inc.'s business segments — D&A has grown at a 2.1% compound annual growth rate (CAGR), from $41.86M to $44.52M.
- What does business segments — D&A mean?
- The non-cash expense allocated to the segment representing the systematic allocation of the cost of tangible and intangible assets over their useful lives. It reflects the consumption of capital assets required to maintain segment operations. Monitoring this helps assess the segment's capital intensity and asset replacement needs.
Ask your AI about Sarepta Therapeutics, Inc.'s business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude